Reflections on ASH 2015 From Dr. Susan O’Brien

http://youtu.be/bC8Jtfsyk5U On location at the American Society of Hematology (ASH) 2015 meeting, CLL expert Dr. Susan O’Brien of the University of California, Irvine, answers several questions about frontline treatment for patients at different stages of CLL. Dr. O’Brien discusses treatment for relapsed-refractory patients, toxicity concerns and 17p deletion, as well as shares her excitement for possible FDA approval by 2017 for rituximab (Rituxan) in combination treatments. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo